[go: up one dir, main page]

AU3804397A - Hexameric fusion proteins and uses therefor - Google Patents

Hexameric fusion proteins and uses therefor

Info

Publication number
AU3804397A
AU3804397A AU38043/97A AU3804397A AU3804397A AU 3804397 A AU3804397 A AU 3804397A AU 38043/97 A AU38043/97 A AU 38043/97A AU 3804397 A AU3804397 A AU 3804397A AU 3804397 A AU3804397 A AU 3804397A
Authority
AU
Australia
Prior art keywords
fusion proteins
uses therefor
hexameric fusion
hexameric
therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38043/97A
Inventor
Margery Ann Chaikin
Sally Doreen Patricia Lyn
Raymond Whitney Sweet
Alemseged Truneh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU3804397A publication Critical patent/AU3804397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU38043/97A 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor Abandoned AU3804397A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1993496P 1996-06-14 1996-06-14
US60019934 1996-06-14
US4394897P 1997-02-19 1997-02-19
US60043948 1997-02-19
US3891597P 1997-02-21 1997-02-21
US60038915 1997-02-21
PCT/US1997/012599 WO1997047732A2 (en) 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor

Publications (1)

Publication Number Publication Date
AU3804397A true AU3804397A (en) 1998-01-07

Family

ID=27361321

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38043/97A Abandoned AU3804397A (en) 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor

Country Status (5)

Country Link
EP (1) EP0975355A2 (en)
JP (1) JP2000515731A (en)
AU (1) AU3804397A (en)
CA (1) CA2257861A1 (en)
WO (1) WO1997047732A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044129A1 (en) * 1997-03-27 1998-10-08 The Council Of The Queensland Institute Of Medical Research Enhancement of immune response using targeting molecules
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6875904B2 (en) 2000-09-20 2005-04-05 The Ohio State University Research Foundation Animal model for identifying agents that inhibit or enhance CTLA4 signaling
WO2003040311A2 (en) 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
CA2516834C (en) 2003-02-27 2013-07-16 Theravision Gmbh Polypeptides and methods for making the same
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
CN104736174B (en) * 2012-07-06 2019-06-14 根马布私人有限公司 Protein dimer with triple mutant
PT2869845T (en) * 2012-07-06 2019-12-09 Genmab Bv Dimeric protein with triple mutations
EP3137506B1 (en) 2014-05-02 2023-08-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
JP6955445B2 (en) 2015-04-07 2021-10-27 ジェネンテック， インコーポレイテッド Antigen binding complex with agonistic activity and how to use it
US11623964B2 (en) 2016-05-23 2023-04-11 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
CN110650748B (en) 2017-01-06 2024-01-02 动量制药公司 Compositions and methods related to engineered Fc constructs
AU2019368289A1 (en) * 2018-10-23 2021-04-29 Igm Biosciences, Inc. Multivalent IgM- and IgA-Fc-based binding molecules

Also Published As

Publication number Publication date
JP2000515731A (en) 2000-11-28
WO1997047732A2 (en) 1997-12-18
CA2257861A1 (en) 1997-12-18
WO1997047732A3 (en) 1998-01-29
EP0975355A2 (en) 2000-02-02

Similar Documents

Publication Publication Date Title
AU6241698A (en) Tace-like and matrilysin-like polypeptides
AU4922497A (en) Interleukin-18-receptor proteins
AU6058500A (en) Fusion protein and uses thereof
AU9482098A (en) Fusion protein systems
AU5065198A (en) Fusion proteins having increased half-lives
AU9781998A (en) Huchordin and uses thereof
AU6721696A (en) Cd44-like protein
AU6266798A (en) Disposable multi-sampler and fitment
AU2572797A (en) Adam proteins and uses thereof
AU4413096A (en) Phenylalanine free proteins
AU3804397A (en) Hexameric fusion proteins and uses therefor
AU2316797A (en) Shc proteins
GB9705903D0 (en) VP22 Proteins and uses thereof
AU3902297A (en) Two human nsp-like proteins
AU6873596A (en) Allergen-xcd32 fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
AU2396600A (en) Secreted proteins and uses thereof
AU3305197A (en) Non-activated receptor complex proteins and uses thereof
AU2377097A (en) Antiviral ricin-like proteins
AU9105698A (en) Rab proteins
AU6000698A (en) Proteins
AU4843297A (en) Anti-obesity proteins
AU5284296A (en) Immune-evading proteins
AU3645097A (en) Chondrocyte proteins
AU2801697A (en) Secreted proteins